National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Evolocumab (Repatha®) is indicated for both primary hypercholesterolaemia and mixed dyslipidaemia and heterozygous familial hypercholesterolaemia.

 

NCPE Assessment Process Complete
NCPE assessment process completed 2016 October 2016
NCPE assessment outcome 2016 Reimbursement not recommended

Summary 2016

NCPE Assessment Process Ongoing
Full pharmacoeconomic assessment recommissioned by HSE 31/05/2017
Pre-submission consultation with applicant 27/06/2017
Submission received from applicant 31/10/2017
Current status NCPE assessment ongoing